Abstract
Evans syndrome (ES) is a rare autoimmune disorder characterized by the co-occurrence or sequential development of autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP), and less frequently, neutropenia. It is a diagnosis of exclusion that can be challenging to recognize due to its nonspecific presentation and overlap with other hematologic or autoimmune disorders. We report the case of a 35-year-old previously healthy male who presented with generalized weakness and extensive bruising. He was hemodynamically stable on admission but exhibited diffuse petechiae and ecchymoses without evidence of hepatosplenomegaly or lymphadenopathy. Laboratory evaluation revealed severe normocytic anemia and profound thrombocytopenia, along with biochemical markers of hemolysis. The direct antiglobulin test (DAT) was positive for IgG, consistent with warm AIHA. The peripheral smear showed marked anisopoikilocytosis, slight schistocytosis, moderate hypochromasia, microspherocytes, and a markedly reduced platelet count. A comprehensive workup, including autoimmune and infectious panels, was unremarkable. Bone marrow biopsy demonstrated erythroid hyperplasia, increased immature megakaryocytes, and no evidence of malignancy, supporting a diagnosis of ES. The patient required multiple transfusions and was treated with high-dose corticosteroids, intravenous immunoglobulin (IVIG), and rituximab, with gradual improvement in cell counts. Second-line agents, such as eltrombopag, represent important therapeutic options in refractory cases, although they were not required for this patient. This case highlights the importance of maintaining a high index of suspicion for ES in patients presenting with unexplained cytopenias, particularly when evidence of hemolysis is present. Early identification and prompt initiation of immunosuppressive therapy can improve outcomes in this potentially life-threatening condition.